Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: safety is protecting from or not exposed to danger or risk

August 6, 2021 8:04am

it’s risky going forward and it could be a long fall down for some sector equities; two (2) examples, since Monday the IBB has advanced +5.37% and the XBI +4.92% with the Nasdaq in its fourth straight positive session

News: Athersys’ (ATHX) partner in Japan, HEALIOS K.K. (Healios) releasing positive topline data from its ONE-BRIDGE clinical trial evaluating the safety and efficacy of MultiStem® cell therapy (invimestrocel) in patients with acute respiratory distress syndrome (ARDS).

Earnings’ releases today: Cellectis SA (CLLS)

Pre-open indications: 1 BUY; 5 SELL with Negative Indications: 6 SELLs into Strength; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Dow futures are UP +0.07% (+23 points), S&P futures are UP +0.05% (+2 points) and NASDAQ futures are DOWN -0.12% (-19 points) pre jobs report

U.S. stock index futures were flat with the Nasdaq down thus, mixed during early morning trading on Friday, ahead of the highly anticipated jobs report,

European markets were soft

Asia-Pacific were mixed as rising Covid cases continued to weigh on sentiment

Data Docket: jobs report, which will show how the labor marked fared during July. Today’s report comes after the weekly initial claims number reported on Thursday came in at 385,000, which was in-line with expectations.

Henry’omics:

Earnings still in focus

Stocks finished Thursday’s session in the green, with the S&P 500 rising 0.6% to close at a new record, while the Dow gained 271.58 points, or 0.78% and the Nasdaq advanced 0.78% for its fourth straight positive session. <CNBC>

Another sign: Bayer AG agreed to buy U.S. biotech company Vividion Therapeutics Inc. for as much as $2 billion, snapping up a developer of promising therapies that only weeks ago filed for an initial public offering. Vividion is currently developing therapies against cancers and immune disorders, its technology platform -- which screens the surfaces of proteins for binding targets that are shallower than drugmakers have previously considered -- can basically be applied to any disease area. <Bloomberg>

The jobs report could also create movement in the bond market and volatility in the equity markets.

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:

Net Income:

CRISPR Therapeutics (CRSP);
uniQure NV (QURE);

Net losses:

Ultragenyx Pharmaceuticals (RARE);
Verastem (VSTM)
Alnylam Pharmaceuticals (ALNY);
Sage Therapeutics (SAGE);
Global Blood Therapeutics (GBT)
MiMedx (MDXG)
Ionis Pharmaceuticals (IONS);
Editas Medicine (EDIT);
Vericel (VCEL);
Brainstorm Cell Therapeutics (BCLI);
Intellia Therapeutics (NTLA);
Caladrius Biosciences (CLBS);
Sangamo Therapeutics (SGMO);
Adverum Biotechnologies (ADVM);
Cellectis SA (CLLS) – today, reported last night

Thursday’s evening’s recap: “cell and gene therapy sector’s hot with a low volume rally. Upside percentage moves pushed the value bar although most earnings estimates fell short of expectations while the Advance/Decline (A/D) line bolted the corral” …

The Nasdaq closed UP +114.58 points (+0.78%)
The IBB closed up +1.57% and XBI closed up +3.80%
Sector volume was LOW with 5 of the 29-upside having higher than the 3-month average volume with very LOW volume of 1 of 1-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -0.69 points or -3.84% at 17.28
Thursday’s percentage (%) of the 29-upside were +0.31% (AXGN) to +18.37% (EDIT) while the 1-downside -0.81% (MESO);

Q3/21:

August: 2 positive and 2 negative closes

July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

June: 15 positive and 8 negative closes
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trad without being “pumped”?

Biostage (BSTG) closed flat again on Thursday with 5 shares traded after Wednesday with 50 shares traded after Tuesday’s flat with 616 shares traded after Monday’s -$0.05 to $1.60 with 571 shares traded.

Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

Morning Indications: Safety and portfolio replenishment …

SELL - Negative indications:

Editas Medicine (EDIT), Brainstorm Cell Therapeutics (BCLI), Cellectis SA (CLLS), Fate Therapeutics (FATE), Sage Therapeutics (SAGE),

SELL into STRENGTH:

Ionis Pharmaceuticals (IONS), Intellia Therapeutics (NTLA), bluebird bio (BLUE), Global Blood Therapeutics (GBT), CRISPR Therapeutics (CRSP), Ultragenyx Pharmaceuticals (RARE),

BUY:

Athersys (ATHX) is popping in the pre-market +$0.25 or +16.23% on news … https://ssl4.eir-parts.net/doc/4593/tdnet/2010473/00.pdf

Pluristem (PSTI) with a positive pre-open indication of +$0.13 or +4.13%.

The BOTTOM LINE:

I am VERY skittish over today, Friday’s cell and gene therapy sector (dramatic upside move put a real edge on share pricing) as earnings continued to guide sector sentiment … this week after sixteen (16) releases to date.

Q2 earnings potential LPS (loss-per-share):

Cellectis SA (CLLS)

Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.

Risk is no doubt increasing as we head into the troublesome August and September months

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

My motto, never leave an investor uninformed about what I know!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.